Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation

Steven Z. Pavletic, Robert G Bociek, James M. Foran, Ronald J. Rubocki, Charles A. Kuszynski, James Lowell Wisecarver, Lori Hatcher, David M. Lucas, John C. Byrd, Michael R. Grever, Shantaram S Joshi, Penny Hardiman, Lynette M Smith, Timothy R McGuire, Philip Jay Bierman, Julie Marie Vose, James Olen Armitage, James E Talmadge

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Nonmyeloablative allogeneic stem-cell transplantation (alloNST) is the focus of investigations searching for less-toxic transplantation regimens. We report studies on the kinetics of lymphodepletion and safety of pentostatin (PT) conditioning in alloNST. Patients with hematologic malignancy received mobilized blood from human leukocyte antigen-matched related (n=4) or unrelated (n=8) donors. PT 4 mg/m2 was administered on days -21, -20, and -19 and 200 cGy of total-body irradiation was administered on day -1, followed by cyclosporine A and mycophenolate mofetil. Mononuclear cell adenosine deaminase after PT was inhibited 84%. The absolute CD3+ cells decreased significantly by day -7 (49%) and CD19+ cells declined 92% by day -1. CD4+ cells were depressed more than CD8+ cells. Neutrophils and monocytes were minimally affected by PT. Median posttransplant peripheral blood chimerism on day 70 showed 95% donor leukocytes and 82.5% donor CD3 lymphocytes. PT demonstrated lymphodepleting effects and promising safety, supporting alloNST as early as 7 days after initiation of PT.

Original languageEnglish (US)
Pages (from-to)877-881
Number of pages5
JournalTransplantation
Volume76
Issue number5
DOIs
StatePublished - Sep 15 2003

Fingerprint

Pentostatin
Stem Cell Transplantation
Safety
Tissue Donors
Mycophenolic Acid
Chimerism
Adenosine Deaminase
Whole-Body Irradiation
Poisons
Hematologic Neoplasms
HLA Antigens
Cyclosporine
Monocytes
Neutrophils
Leukocytes
Transplantation
Lymphocytes

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation. / Pavletic, Steven Z.; Bociek, Robert G; Foran, James M.; Rubocki, Ronald J.; Kuszynski, Charles A.; Wisecarver, James Lowell; Hatcher, Lori; Lucas, David M.; Byrd, John C.; Grever, Michael R.; Joshi, Shantaram S; Hardiman, Penny; Smith, Lynette M; McGuire, Timothy R; Bierman, Philip Jay; Vose, Julie Marie; Armitage, James Olen; Talmadge, James E.

In: Transplantation, Vol. 76, No. 5, 15.09.2003, p. 877-881.

Research output: Contribution to journalArticle

Pavletic, Steven Z. ; Bociek, Robert G ; Foran, James M. ; Rubocki, Ronald J. ; Kuszynski, Charles A. ; Wisecarver, James Lowell ; Hatcher, Lori ; Lucas, David M. ; Byrd, John C. ; Grever, Michael R. ; Joshi, Shantaram S ; Hardiman, Penny ; Smith, Lynette M ; McGuire, Timothy R ; Bierman, Philip Jay ; Vose, Julie Marie ; Armitage, James Olen ; Talmadge, James E. / Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation. In: Transplantation. 2003 ; Vol. 76, No. 5. pp. 877-881.
@article{2986ea489b4740ad836ab1c9f364927c,
title = "Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation",
abstract = "Nonmyeloablative allogeneic stem-cell transplantation (alloNST) is the focus of investigations searching for less-toxic transplantation regimens. We report studies on the kinetics of lymphodepletion and safety of pentostatin (PT) conditioning in alloNST. Patients with hematologic malignancy received mobilized blood from human leukocyte antigen-matched related (n=4) or unrelated (n=8) donors. PT 4 mg/m2 was administered on days -21, -20, and -19 and 200 cGy of total-body irradiation was administered on day -1, followed by cyclosporine A and mycophenolate mofetil. Mononuclear cell adenosine deaminase after PT was inhibited 84{\%}. The absolute CD3+ cells decreased significantly by day -7 (49{\%}) and CD19+ cells declined 92{\%} by day -1. CD4+ cells were depressed more than CD8+ cells. Neutrophils and monocytes were minimally affected by PT. Median posttransplant peripheral blood chimerism on day 70 showed 95{\%} donor leukocytes and 82.5{\%} donor CD3 lymphocytes. PT demonstrated lymphodepleting effects and promising safety, supporting alloNST as early as 7 days after initiation of PT.",
author = "Pavletic, {Steven Z.} and Bociek, {Robert G} and Foran, {James M.} and Rubocki, {Ronald J.} and Kuszynski, {Charles A.} and Wisecarver, {James Lowell} and Lori Hatcher and Lucas, {David M.} and Byrd, {John C.} and Grever, {Michael R.} and Joshi, {Shantaram S} and Penny Hardiman and Smith, {Lynette M} and McGuire, {Timothy R} and Bierman, {Philip Jay} and Vose, {Julie Marie} and Armitage, {James Olen} and Talmadge, {James E}",
year = "2003",
month = "9",
day = "15",
doi = "10.1097/01.TP.0000084869.08639.A0",
language = "English (US)",
volume = "76",
pages = "877--881",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation

AU - Pavletic, Steven Z.

AU - Bociek, Robert G

AU - Foran, James M.

AU - Rubocki, Ronald J.

AU - Kuszynski, Charles A.

AU - Wisecarver, James Lowell

AU - Hatcher, Lori

AU - Lucas, David M.

AU - Byrd, John C.

AU - Grever, Michael R.

AU - Joshi, Shantaram S

AU - Hardiman, Penny

AU - Smith, Lynette M

AU - McGuire, Timothy R

AU - Bierman, Philip Jay

AU - Vose, Julie Marie

AU - Armitage, James Olen

AU - Talmadge, James E

PY - 2003/9/15

Y1 - 2003/9/15

N2 - Nonmyeloablative allogeneic stem-cell transplantation (alloNST) is the focus of investigations searching for less-toxic transplantation regimens. We report studies on the kinetics of lymphodepletion and safety of pentostatin (PT) conditioning in alloNST. Patients with hematologic malignancy received mobilized blood from human leukocyte antigen-matched related (n=4) or unrelated (n=8) donors. PT 4 mg/m2 was administered on days -21, -20, and -19 and 200 cGy of total-body irradiation was administered on day -1, followed by cyclosporine A and mycophenolate mofetil. Mononuclear cell adenosine deaminase after PT was inhibited 84%. The absolute CD3+ cells decreased significantly by day -7 (49%) and CD19+ cells declined 92% by day -1. CD4+ cells were depressed more than CD8+ cells. Neutrophils and monocytes were minimally affected by PT. Median posttransplant peripheral blood chimerism on day 70 showed 95% donor leukocytes and 82.5% donor CD3 lymphocytes. PT demonstrated lymphodepleting effects and promising safety, supporting alloNST as early as 7 days after initiation of PT.

AB - Nonmyeloablative allogeneic stem-cell transplantation (alloNST) is the focus of investigations searching for less-toxic transplantation regimens. We report studies on the kinetics of lymphodepletion and safety of pentostatin (PT) conditioning in alloNST. Patients with hematologic malignancy received mobilized blood from human leukocyte antigen-matched related (n=4) or unrelated (n=8) donors. PT 4 mg/m2 was administered on days -21, -20, and -19 and 200 cGy of total-body irradiation was administered on day -1, followed by cyclosporine A and mycophenolate mofetil. Mononuclear cell adenosine deaminase after PT was inhibited 84%. The absolute CD3+ cells decreased significantly by day -7 (49%) and CD19+ cells declined 92% by day -1. CD4+ cells were depressed more than CD8+ cells. Neutrophils and monocytes were minimally affected by PT. Median posttransplant peripheral blood chimerism on day 70 showed 95% donor leukocytes and 82.5% donor CD3 lymphocytes. PT demonstrated lymphodepleting effects and promising safety, supporting alloNST as early as 7 days after initiation of PT.

UR - http://www.scopus.com/inward/record.url?scp=0141478854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141478854&partnerID=8YFLogxK

U2 - 10.1097/01.TP.0000084869.08639.A0

DO - 10.1097/01.TP.0000084869.08639.A0

M3 - Article

VL - 76

SP - 877

EP - 881

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 5

ER -